Investigators report findings from the use of an all-oral regimen of bedaquiline, pretomanid, and linezolid in patients in the United States with multidrug-resistant or extensively drug-resistant tuberculosis.
Neela D. Goswami, M.D., M.P.H.
Centers for Disease Control and Prevention, Atlanta, GA
David Ashkin, M.D.
Connie A. Haley, M.D.
University of Florida, Gainesville, FL
for the BAM Project Team
Funding and Disclosures
A list of the BAM Project Team investigators is available in the Supplementary Appendix, available at NEJM.org.
Print Subscriber? Activate your online access.